The antitrust authorities in Germany, USA (Federal Trade Commission) and Spain have unconditionally cleared the acquisition of a controlling stake in Stedim Biosystems by Sartorius
Thus, from an antitrust point of view, the path is clear for merging the biotechnology activities of the two companies into Sartorius Stedim Biotech.
Currently, essential parts of the transaction are still subject to clearance by the French exchange supervisory authority (AMF) and approval by the shareholders' meeting of Stedim Biosystems.
Sartorius plans to complete this transaction in summer 2007.
On 22 February 2007, Sartorius had announced that it had signed an agreement to acquire a controlling stake in the French biotechnology supplier Stedim Biosystems.
in order to further strengthen its dynamically growing and highly profitable biotechnology activities.
It is planned to combine the Sartorius biotechnology division with Stedim into an independent biotechnology subgroup in which Sartorius will hold the majority of the voting rights and which Sartorius will fully consolidate in its annual financial statements.
